Table 1.
Parameter | Not Demethylated SST1 ΔRDL < 1.0 | Moderately Demethylated SST1 ΔRDL > 1.0 & < 3.0 |
Strongly Demethylated SST1 ΔRDL > 3.0 | Fisher’s Test p-Value |
---|---|---|---|---|
Gender | Women (n = 59) | Women (n = 6) | Women (n = 2) | p1 = 0.19 |
Men (n = 64) | Men (n = 12) | Men (n = 5) | p2 = 0.46 | |
Age | <66 y/o (n = 57) | <66 y/o (n = 10) | <66 y/o (n = 5) | p1 = 0.27 |
>66 y/o (n = 66) | >66 y/o (n = 8) | >66 y/o (n = 2) | p2 = 0.27 | |
Ethnic | Caucasian (n = 94) | Caucasian (n = 9) | Caucasian (n = 3) | p1 = 0.05 |
Afr.Am. (n = 18) | Afr.Am. (n = 6) | Afr.Am. (n = 1) | p2 = 0.58 | |
Tumor Location | Proximal (n = 69) | Proximal (n = 10) | Proximal (n = 2) | p1 = 0.38 |
Distal (n = 50) | Distal (n = 8) | Distal (n = 5) | p2 = 0.24 | |
Dukes’ stage | IS-A-B (n = 52) | IS-A-B (n = 9) | IS-A-B (n = 4) | p1 = 0.39 |
C-D-M (n = 71) | C-D-M (n = 9) | C-D-M (n = 3) | p2 = 0.70 | |
MSI status | MSS (n = 102) | MSS (n = 17) | MSS (n = 6) | p1 = 0.37 |
MSI (n = 21) | MSI (n = 1) | MSI (n = 1) | p2 = 1.00 | |
TP53 | WT (n = 44) | WT (n = 5) | WT (n = 0) | p1 = 0.0037 ** |
MUT (n = 32) | MUT (n = 11) | MUT (n = 7) | p2 = 0.012 * | |
KRAS | WT (n = 75) | WT (n = 12) | WT (n = 7) | p1 = 0.18 |
MUT (n = 48) | MUT (n = 6) | MUT (n = 0) | p2 = 0.048 * | |
BRAF | WT (n = 112) | WT (n = 16) | WT (n = 4) | p1 = 0.25 |
MUT (n = 10) | MUT (n = 2) | MUT (n = 2) | p2 = 0.10 |
p1: Fisher’s test p-value comparing not-demethylated tumors vs. the rest (demethylated and strongly demethylated). p2: Fisher’s test p-value comparing strongly demethylated tumors vs. the rest. *: p-value < 0.05. **: p-value < 0.01. In parenthesis, the number of informative cases in each category. In Ethnic, Afr.Am.: African American. In Duke’s stage, tumors were grouped into in situ (IS, n = 1), Duke’s A (n = 7) and Duke’s B (B, n = 54) vs. Duke’s C (n = 58), Duke’s D (n = 23) and metastases (M, n = 2). WT: wild-type. MUT: mutant. Some of the total number of samples do not match the total 148 cases sample due to incomplete information.